Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cuckle H. S., Richardson G. A., Sheldon T. A., Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ. 1995 Dec 2;311(7018):1460–1464. doi: 10.1136/bmj.311.7018.1460. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jenks S. NCI plans national cancer genetics network. J Natl Cancer Inst. 1996 May 1;88(9):579–580. doi: 10.1093/jnci/88.9.579. [DOI] [PubMed] [Google Scholar]
- Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. [PMC free article] [PubMed] [Google Scholar]
- Lieu T. A., Watson S. E., Washington A. E. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol. 1994 Dec;84(6):903–912. [PubMed] [Google Scholar]
- Mehlman M. J., Botkin J. R., Scarrow A., Woodhall A., Kass J., Siebenschuh E. Coverage of genetic technologies under national health reform. Am J Hum Genet. 1994 Nov;55(5):1054–1060. [PMC free article] [PubMed] [Google Scholar]
- Noorani H. Z., Khan H. N., Gallie B. L., Detsky A. S. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet. 1996 Aug;59(2):301–307. [PMC free article] [PubMed] [Google Scholar]
- Pauker S. G., Kassirer J. P. Decision analysis. N Engl J Med. 1987 Jan 29;316(5):250–258. doi: 10.1056/NEJM198701293160505. [DOI] [PubMed] [Google Scholar]
- Smith T. J., Hillner B. E., Desch C. E. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst. 1993 Sep 15;85(18):1460–1474. doi: 10.1093/jnci/85.18.1460. [DOI] [PubMed] [Google Scholar]